| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Deapi-platycodin D3 targets the pathways involved in airway mucin production and secretion. It regulates the production and secretion of airway mucin, which explains its traditional use as an expectorant in inflammatory pulmonary diseases. As a triterpenoid saponin, the compound may also interact with inflammatory signaling pathways, contributing to its anti-inflammatory effects. Its ability to regulate mucin production suggests interactions with airway epithelial cells and the signaling pathways that control mucin gene expression and secretion.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that deapi-platycodin D3 can regulate the production and secretion of airway mucin in cell-based models. Its activity as an expectorant has been documented in various in vitro models of airway inflammation and mucin production. However, detailed in vitro potency data, such as IC₅₀ values or specific cellular effects, are not extensively documented in the available literature. The compound's ability to regulate mucin production makes it a valuable tool for studying airway inflammation and mucin biology.
|
| ln Vivo |
In vivo, deapi-platycodin D3 contributes to the expectorant effects of Platycodon grandiflorum root extract in diverse inflammatory pulmonary diseases. Its ability to regulate airway mucin production and secretion explains the traditional use of the plant as an expectorant. The compound's anti-inflammatory effects may contribute to its overall therapeutic benefits in pulmonary diseases. However, comprehensive in vivo efficacy and safety studies for deapi-platycodin D3 as a single agent are limited. The compound's natural occurrence in Platycodon grandiflorum, which has a long history of use in traditional medicine, supports its potential as a therapeutic agent.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for deapi-platycodin D3 are not standard, as its mechanism is primarily studied in cell-based systems. However, the compound's effects on mucin production can be assessed using cell-free systems to measure the activity of enzymes involved in mucin synthesis or degradation. These assays provide quantitative data on the compound's direct effects on specific molecular targets involved in mucin biology.
|
| Cell Assay |
In vitro cell-based assays for deapi-platycodin D3 use airway epithelial cell lines to study its effects on mucin production and secretion. Cells are cultured in appropriate media and treated with varying concentrations of the compound. Parameters such as mucin production (by ELISA or Western blotting), mucin gene expression (by qPCR), and inflammatory cytokine production (by ELISA) are assessed. Cell viability is assessed using MTT or similar assays. These studies help to characterize the compound's cellular mechanism of action and its effects on airway inflammation.
|
| Animal Protocol |
In vivo animal studies for deapi-platycodin D3 would likely employ models of inflammatory pulmonary diseases, such as chronic obstructive pulmonary disease (COPD) or asthma. The compound is administered orally or intraperitoneally, and parameters such as airway mucin production, inflammatory cell infiltration, and cytokine levels in bronchoalveolar lavage fluid (BALF) are assessed. Histopathological examination of lung tissues is performed to evaluate the compound's effects on airway inflammation and mucin production. Pharmacokinetic studies in these models provide information about the compound's absorption, distribution, metabolism, and excretion.
|
| ADME/Pharmacokinetics |
Deapi-platycodin D3 has a molecular weight of 1255.35 g/mol and a molecular formula of C₅₈H₉₄O₂₉. It is a triterpenoid saponin that appears as a white crystalline powder. The compound is practically insoluble in water (0.015 g/L at 25°C) and has a density of 1.57±0.1 g/cm³ at 20°C. It should be stored under appropriate conditions as recommended by the manufacturer. Detailed pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion have not been extensively characterized. As a saponin with a high molecular weight, deapi-platycodin D3 is expected to have poor oral bioavailability.
|
| Toxicity/Toxicokinetics |
The toxicity profile of deapi-platycodin D3 has not been comprehensively evaluated in published studies. As a natural saponin from Platycodon grandiflorum, which has a long history of use in traditional medicine, it is generally considered to have low to moderate toxicity. Saponins can have hemolytic activity and may cause gastrointestinal irritation at high doses. The compound is classified as a research reagent and is not intended for human therapeutic use without further safety evaluation. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Deapio-platycodin D3 is a triterpenoid saponin that acts as a metabolite. It has been reported that Platycodon grandiflorus contains Deapio-platycodin D3, and relevant data are available for reference.
Deapi-platycodin D3 is a triterpenoid saponin isolated from the root of Platycodon grandiflorum A. de Candolle. It is also known as 去芹糖桔梗皂苷D3 in Chinese. The compound can regulate the production and secretion of airway mucin, explaining the traditional use of the plant as an expectorant in diverse inflammatory pulmonary diseases. It appears as a white crystalline powder and is practically insoluble in water. Not approved for clinical use; intended for research purposes only. |
| Molecular Formula |
C58H94O29
|
|---|---|
| Molecular Weight |
1255.3496
|
| Exact Mass |
1254.588
|
| CAS # |
67884-05-3
|
| PubChem CID |
70698190
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Index of Refraction |
1.662
|
| LogP |
-0.59
|
| Hydrogen Bond Donor Count |
18
|
| Hydrogen Bond Acceptor Count |
29
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
87
|
| Complexity |
2420
|
| Defined Atom Stereocenter Count |
33
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H](CO[C@H]2OC(=O)[C@]34CCC(C[C@H]3C5=CC[C@H]6[C@]([C@@]5(C[C@H]4O)C)(CC[C@@H]7[C@@]6(C[C@@H]([C@@H](C7(CO)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O)O)O)C)C)(C)C)O)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H](CO1)O)O)O
|
| InChi Key |
QDTKFVBGHXCISC-UEZGXTIOSA-N
|
| InChi Code |
InChI=1S/C58H94O29/c1-22-44(84-48-40(73)33(66)26(63)17-78-48)39(72)43(76)49(81-22)85-45-34(67)27(64)18-79-51(45)87-52(77)58-12-11-53(2,3)13-24(58)23-7-8-30-54(4)14-25(62)46(57(20-60,21-61)31(54)9-10-55(30,5)56(23,6)15-32(58)65)86-50-42(75)38(71)36(69)29(83-50)19-80-47-41(74)37(70)35(68)28(16-59)82-47/h7,22,24-51,59-76H,8-21H2,1-6H3/t22-,24-,25-,26+,27-,28+,29+,30+,31+,32+,33-,34-,35+,36+,37-,38-,39-,40+,41+,42+,43+,44-,45+,46-,47+,48-,49-,50-,51-,54+,55+,56+,58+/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5S)-3-[(2S,3R,4S,5R,6S)-3,4-dihydroxy-6-methyl-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl] (4aR,5R,6aR,6aS,6bR,8aR,10R,11S,12aR,14bS)-5,11-dihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-10-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~79.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7966 mL | 3.9830 mL | 7.9659 mL | |
| 5 mM | 0.1593 mL | 0.7966 mL | 1.5932 mL | |
| 10 mM | 0.0797 mL | 0.3983 mL | 0.7966 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
